Verve Therapeutics (VERV) Revenue & Revenue Breakdown
Verve Therapeutics Revenue Highlights
Latest Revenue (Y)
$11.76M
Latest Revenue (Q)
$5.70M
Verve Therapeutics Revenue by Period
Verve Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $11.76M | 505.77% |
| 2022-12-31 | $1.94M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Verve Therapeutics generated $11.76M in revenue during NA 2023, up 505.77% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Verve Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $5.70M | 10.71% |
| 2023-12-31 | $5.14M | 65.03% |
| 2023-09-30 | $3.12M | 48.92% |
| 2023-06-30 | $2.09M | 49.07% |
| 2023-03-31 | $1.40M | 38.74% |
| 2022-12-31 | $1.01M | 8.93% |
| 2022-09-30 | $929.00K | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Verve Therapeutics generated $5.70M in revenue during Q1 2024, up 10.71% compared to the previous quarter, and up 562.75% compared to the same period a year ago.
Verve Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BEAM | Beam Therapeutics | $377.71M | $11.77M |
| CRSP | CRISPR Therapeutics | $370.00M | $517.00K |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| ADPT | Adaptive Bio | $170.28M | $43.19M |
| NTLA | Intellia Therapeutics | $36.27M | $6.96M |
| CRBU | Caribou Biosciences | $34.48M | $3.46M |
| RLAY | Relay Therapeutics | $25.55M | - |
| VERV | Verve Therapeutics | $11.76M | $5.70M |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| EDIT | Editas Medicine | - | - |
| PRME | Prime Medicine | - | - |
| SANA | Sana Bio | - | - |
VERV Revenue FAQ
What is Verve Therapeutics’s yearly revenue?
Verve Therapeutics's yearly revenue for 2023 was $11.76M, representing an increase of 505.77% compared to 2022. The company's yearly revenue for 2022 was $1.94M, representing an increase of 100.00% compared to 2021. VERV's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Verve Therapeutics’s quarterly revenue?
Verve Therapeutics's quarterly revenue for Q1 2024 was $5.7M, a 10.71% increase from the previous quarter (Q4 2023), and a 305.63% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $5.14M, a 65.03% increase from the previous quarter (Q3 2023), and a 408.30% increase year-over-year (Q4 2022). VERV's quarterly revenue for Q3 2023 was $3.12M, a 48.92% increase from the previous quarter (Q2 2023), and a 235.52% increase year-over-year (Q3 2022).
What is Verve Therapeutics’s revenue growth rate?
Verve Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.